Prospective Grant of Exclusive License: Ophthalmic Diagnostic Devices, 42531-42532 [2013-16950]
Download as PDF
<![CDATA[
Federal Register / Vol. 78, No. 136 / Tuesday, July 16, 2013 / Notices
Patent application
No.
NIH Ref. No.
NIH
NIH
NIH
NIH
Ref.
Ref.
Ref.
Ref.
E–155–2005/3–CA–05 ................................................................
E–155–2005/3–EP–03 (CH, DE, FR, GB, and IE) .....................
E–155–2005/3–PCT–01 ..............................................................
E–155–2005/3–US–02 ................................................................
to Georgia Health Sciences University
Research Institute, Inc. having a
principal place of business in Augusta,
Georgia.
The United States of America is an
assignee to the patent rights of these
inventions.
The contemplated exclusive license
may be in a field of use directed to
cervical cancer vaccines.
DATES: Only written comments and/or
applications for a license that are
received by the NIH Office of
Technology Transfer on or before
August 15, 2013 will be considered.
ADDRESSES: Requests for a copy of the
patent application, inquiries, comments
and other materials relating to the
contemplated license should be directed
to: Michael Shmilovich, Esq, CLP,
Senior Licensing and Patent Manager,
Office of Technology Transfer, National
Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville, MD
20852–3804; Telephone: (301) 435–
5019; Facsimile: (301) 402–0220; Email:
shmilovm@od.nih.gov. A signed
confidential disclosure agreement may
be required to receive copies of patent
applications assuming it has not already
issued or been published under either
the publication rules of either the US
Patent and Trademark Office or World
Intellectual Property Organization.
SUPPLEMENTARY INFORMATION:
emcdonald on DSK67QTVN1PROD with NOTICES
NIH Ref. No. E–155–2005/0–3 (as
Above)
The invention pertains primarily to
CD8+ T cell epitopes from HPV16 E2.
These epitopes generated from amino
acid positions 69–77 (ALQAIELQL) and
138–147 (YICEEASVTV) bind to
HLA.A2 and elicit CD8+ cytotoxic T cell
responses that lyse tumor cells of lowgrade cervical neoplasia (wart).
NIH Ref. No. E–126–2001/0 (as Above)
Immunogenic peptides from the HPV–
18E6 (X1KLPDLCTELX2;, wherein X2
and X1 are peptides of 0–11 amino acids
in length comprising contiguous HPV 18
E6 amino acid sequences) protein that
comprise class I restricted T cell
epitopes and methods of administering
the same. The HPV–18E6 peptide crossreacts immunologically with both HPV
type 16 and HPV type 18 with higher
affinity than most common human
lymphocyte antigen (HLA), HLA–A2
VerDate Mar<15>2010
18:49 Jul 15, 2013
Jkt 229001
42531
Filing date
Issued patent no.
(if any)
2604909
6749659.6
PCT/US2006/1331
11/918,557
April 11, 2006 .....................
April 11, 2007 .....................
April 11, 2006 .....................
October 11, 2006 ...............
..............................
1877087
(Expired)
7,691,579
than the homologous peptide from HPV
16. E6 peptide vaccines are potentially
prophylactic or therapeutic for cervical
cancer, other genital cancers, head and
neck cancers, and upper digestive tract
cancers. It could also be potentially
used in the treatment of patients
presenting with pre-malignant cervical
disease, especially in underdeveloped
countries with no access to surgical
treatment or to completely avoid
surgical treatment.
The prospective exclusive license will
be royalty-bearing and comply with the
terms and conditions of 35 U.S.C. 209
and 37 CFR part 404. The prospective
exclusive license may be granted unless,
within thirty (30) days from the date of
this published notice, NIH receives
written evidence and argument that
establishes that the grant of the license
would not be consistent with the
requirements of 35 U.S.C. 209 and 37
CFR part 404.
Properly filed competing applications
for a license filed in response to this
notice will be treated as objections to
the contemplated license. Comments
and objections submitted in response to
this notice will not be made available
for public inspection, and, to the extent
permitted by law, will not be released
under the Freedom of Information Act,
5 U.S.C. 552.
Dated: July 9, 2013.
Richard Rodriguez,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. 2013–16949 Filed 7–15–13; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusive
License: Ophthalmic Diagnostic
Devices
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
This is notice, in accordance
with 35 U.S.C. 209 and 37 CFR part 404,
that the National Institutes of Health
(NIH), Department of Health and Human
SUMMARY:
PO 00000
Frm 00046
Fmt 4703
Sfmt 4703
Services (HHS), is contemplating the
grant of a worldwide exclusive start-up
patent license, to practice the inventions
embodied in U.S. Patent 8,132,911 (HHS
Ref. No. E–279–2006/0) to
OptoBiometrics Designs, Inc., a
company incorporated under the laws of
the State of California having its
headquarters in Pleasant Hill,
California. The United States of America
is the assignee of the rights of the above
inventions. The contemplated exclusive
license may be granted in a field of use
limited to ocular fundus examination
devices and systems.
DATES: Only written comments and/or
applications for a license received by
the NIH Office of Technology Transfer
on or before July 31, 2013 will be
considered.
ADDRESSES: Requests for a copy of the
patent application, inquiries, comments
and other materials relating to the
contemplated license should be directed
to: Michael A. Shmilovich, Esq., CLP,
Office of Technology Transfer, National
Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville, MD
20852–3804; Telephone: (301) 435–
5019; Facsimile: (301) 402–0220; Email:
shmilovm@mail.nih.gov. A signed
confidentiality nondisclosure agreement
will be required to receive copies of any
patent applications that have not been
published by the United States Patent
and Trademark Office or the World
Intellectual Property Organization.
SUPPLEMENTARY INFORMATION: The
issued patent covers an optical system
that permits targeted photo-stimulation
of the retina by positioning a stimulus
location under visual guidance through
a fundus camera. The instant system is
designed to elicit, under direct infrared
(IR) visual control of stimulus size and
position in the retina,
electroretinograms (ERGs) in response to
photo-stimulation from selected regions
of the retina, as well as to present small
light stimuli to a selected area to explore
visual sensitivity properties. For
example, the detected ERGs can be the
basis for diagnosing or characterizing
patient retina with early stage retinal
disease versus healthy retina from the
opposite eye. The system can be
mounted on commercially available
fundus cameras that have IR capabilities
(or would accept IR bandpass filtering of
E:\FR\FM\16JYN1.SGM
16JYN1
42532
Federal Register / Vol. 78, No. 136 / Tuesday, July 16, 2013 / Notices
their retinal illumination output) and
will accept a near IR CCD camera
connected to a TV mounted on the
photographic-camera port.
The prospective exclusive license will
be royalty bearing and will comply with
the terms and conditions of 35 U.S.C.
209 and 37 CFR part 404. The
prospective exclusive license may be
granted unless, within fifteen (15) days
from the date of this published notice,
NIH receives written evidence and
argument that establishes that the grant
of the license would not be consistent
with the requirements of 35 U.S.C. 209
and 37 CFR part 404.
Properly filed competing applications
for a license filed in response to this
notice will be treated as objections to
the contemplated license. Comments
and objections submitted in response to
this notice will not be made available
for public inspection, and, to the extent
permitted by law, will not be released
under the Freedom of Information Act,
5 U.S.C. 552.
Dated: July 9, 2013.
Richard U. Rodriguez,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. 2013–16950 Filed 7–15–13; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Prospective Grant of Start-Up
Exclusive Evaluation Option License:
Methods of Treating Giardiasis Using
Available Compounds
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
This is notice, in accordance
with 35 U.S.C. 209 and 37 CFR part 404,
that the National Institutes of Health
(NIH), Department of Health and Human
Services, is contemplating the grant of a
start-up exclusive evaluation option
license to practice the inventions
embodied in U.S. provisional
Applications 61/392,096 (E–211–2010/
0–US–01) filed October 12, 2010 and
61/411,509 filed November 9, 2010 (E–
211–2010/1–US–01); PCT application
No. PCT/US2011/055902 filed October
12, 2011 (E–211–2010/2–PCT–01); US
patent application No. 13/878,832 filed
April 11, 2013 (E–211–2010/2–US–06);
European patent application No.
11773158.8 filed May 2, 2013 (E–211–
2010/2–EP–04); Canadian application
No. 2,814,694 filed April 11, 2013 (E–
emcdonald on DSK67QTVN1PROD with NOTICES
SUMMARY:
VerDate Mar<15>2010
18:49 Jul 15, 2013
Jkt 229001
211–2010/2–CA–03); Australia
application No. 2011316657 filed April
12, 2013 (E–211–2010/2–AU–02); and
Indian application No. 1137/KOLNP/
2013 filed April 22, 2013 (E–211–2010/
2–IN–05); each entitled ‘‘Methods of
Treating Giardiasis’’ by Wei Zheng et al.
to BrioMed, Inc., having a place of
business at 1743 S. Westgate Ave, Los
Angeles, CA 90025 USA. The patent
rights in this invention have been
assigned to the United States of America
and the University of Maryland.
DATES: Only written comments and/or
application for a license that are
received by the NIH Office of
Technology Transfer on or before July
31, 2013 will be considered.
ADDRESSES: Requests for a copy of the
patent application, inquiries, comments
and other materials relating to the
contemplated license should be directed
to: Tedd Fenn, Office of Technology
Transfer, National Institutes of Health,
6011 Executive Boulevard, Suite 325,
Rockville, MD 20852–3804; Email:
Tedd.Fenn@mail.nih.gov; Telephone:
301–435–5031; Facsimile: 301–402–
0220.
SUPPLEMENTARY INFORMATION: The
prospective start-up exclusive
evaluation option license will be royalty
bearing and will comply with the terms
and conditions of 35 U.S.C. 209 and 37
CFR part 404. The prospective start-up
exclusive evaluation option license may
be granted unless, within fifteen (15)
days from the date of this published
Notice, NIH receives written evidence
and argument that establishes that the
grant of the license would not be
consistent with the requirements of 35
U.S.C. 209 and 37 CFR part 404.
This technology includes a group of at
least twenty-nine, diverse, commercially
available compounds that are newly
identified for activity against Giardia
lamblia parasites. At least six of the
candidate compounds, Bortezomib,
Decitabine, Hydroxocobalamin,
Amlexanox, Idarubicin, and Auranofin
have preexisting FDA approval for
human use for other (non-Giardia)
conditions. Another three compounds,
Fumagillin, Nitarsone and Carbadox
have preexisting approval for veterinary
use for non-Giardia conditions.
Additional active compounds identified
include: Acivicin, Riboflavin butyrate,
BTO–1, GW9662, Dinitroph-dfgp,
Deserpidine, Tetramethylthiuram
disulsulfide, Disulfiram, Mitoxantrone,
Ecteinascidin 743, 17allyaminogeldanamycin, Carboquone
and Nocodazole. The anti-Giardial
activity of these compounds presents a
cost saving opportunity for the rapid
development of new, better tolerated
PO 00000
Frm 00047
Fmt 4703
Sfmt 4703
treatments for the most prevalent
human intestinal parasite infection in
the United States and the world.
The proposed field of exclusivity may
be limited to therapeutics for treatment
of Giardia infection in mammals.
Properly filed competing applications
for a license filed in response to this
notice will be treated as objections to
the contemplated license. Comments
and objections submitted in response to
this notice will not be made available
for public inspection, and, to the extent
permitted by law, will not be released
under the Freedom of Information Act,
5 U.S.C. 552.
Dated: July 9, 2013.
Richard U. Rodriguez,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer.
[FR Doc. 2013–16948 Filed 7–15–13; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HOMELAND
SECURITY
Cooperative Research and
Development Agreement (CRADA)
Opportunity With the Department of
Homeland Security for the
Development of a Foot-and-Mouth
Disease 3ABC ELISA Diagnostic Kit;
Correction
Science and Technology
Directorate, Plum Island Animal Disease
Center, Department of Homeland
Security.
ACTION: Notice of intent; correction.
AGENCY:
The Department of Homeland
Security Science and Technology
Directorate (DHS S&T), through its Plum
Island Animal Disease Center (PIADC),
published a document in the Federal
Register of May 16, 2013, seeking
industry collaborators to aid DHS S&T
in developing and validating an ELISA
diagnostic kit for detection of Foot and
Mouth Disease Virus (FMDV) nonstructural proteins. The document did
not specify dates for when the
submission of proposals are due.
FOR FURTHER INFORMATION CONTACT:
Angela Ervin, 202–254–5624.
SUMMARY:
Correction
In the Federal Register of May 16,
2013, in FR Doc. DHS–2013–0036, on
page 1, in the third column, correct the
DATES caption to read:
DATES: Submit proposals on or before
August 8, 2013.
Correction
In the Federal Register of May 16,
2013, in FR Doc. DHS–2013–0036, on
E:\FR\FM\16JYN1.SGM
16JYN1
]]>Agencies
[Federal Register Volume 78, Number 136 (Tuesday, July 16, 2013)]
[Notices]
[Pages 42531-42532]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-16950]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusive License: Ophthalmic Diagnostic
Devices
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: This is notice, in accordance with 35 U.S.C. 209 and 37 CFR
part 404, that the National Institutes of Health (NIH), Department of
Health and Human Services (HHS), is contemplating the grant of a
worldwide exclusive start-up patent license, to practice the inventions
embodied in U.S. Patent 8,132,911 (HHS Ref. No. E-279-2006/0) to
OptoBiometrics Designs, Inc., a company incorporated under the laws of
the State of California having its headquarters in Pleasant Hill,
California. The United States of America is the assignee of the rights
of the above inventions. The contemplated exclusive license may be
granted in a field of use limited to ocular fundus examination devices
and systems.
DATES: Only written comments and/or applications for a license received
by the NIH Office of Technology Transfer on or before July 31, 2013
will be considered.
ADDRESSES: Requests for a copy of the patent application, inquiries,
comments and other materials relating to the contemplated license
should be directed to: Michael A. Shmilovich, Esq., CLP, Office of
Technology Transfer, National Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville, MD 20852-3804; Telephone: (301) 435-
5019; Facsimile: (301) 402-0220; Email: shmilovm@mail.nih.gov. A signed
confidentiality nondisclosure agreement will be required to receive
copies of any patent applications that have not been published by the
United States Patent and Trademark Office or the World Intellectual
Property Organization.
SUPPLEMENTARY INFORMATION: The issued patent covers an optical system
that permits targeted photo-stimulation of the retina by positioning a
stimulus location under visual guidance through a fundus camera. The
instant system is designed to elicit, under direct infrared (IR) visual
control of stimulus size and position in the retina, electroretinograms
(ERGs) in response to photo-stimulation from selected regions of the
retina, as well as to present small light stimuli to a selected area to
explore visual sensitivity properties. For example, the detected ERGs
can be the basis for diagnosing or characterizing patient retina with
early stage retinal disease versus healthy retina from the opposite
eye. The system can be mounted on commercially available fundus cameras
that have IR capabilities (or would accept IR bandpass filtering of
[[Page 42532]]
their retinal illumination output) and will accept a near IR CCD camera
connected to a TV mounted on the photographic-camera port.
The prospective exclusive license will be royalty bearing and will
comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR part
404. The prospective exclusive license may be granted unless, within
fifteen (15) days from the date of this published notice, NIH receives
written evidence and argument that establishes that the grant of the
license would not be consistent with the requirements of 35 U.S.C. 209
and 37 CFR part 404.
Properly filed competing applications for a license filed in
response to this notice will be treated as objections to the
contemplated license. Comments and objections submitted in response to
this notice will not be made available for public inspection, and, to
the extent permitted by law, will not be released under the Freedom of
Information Act, 5 U.S.C. 552.
Dated: July 9, 2013.
Richard U. Rodriguez,
Director, Division of Technology Development and Transfer, Office of
Technology Transfer, National Institutes of Health.
[FR Doc. 2013-16950 Filed 7-15-13; 8:45 am]
BILLING CODE 4140-01-P
